JSM2026
Back to the program
Contributed Papers

Survival Analysis, Count data , Competing Risks & Intercurrent Events

Sun, Aug 2, 2:00 PM - 3:50 PM Room CC-252A Thomas M. Menino Convention & Exhibition Center
Elena PolverejanChair
Biopharmaceutical Section

7 Presentations

Capturing Cumulative Disease Burden in Chronic Kidney Disease Trials Beyond Time-to-First Analysis
2:05 PM - 2:20 PM
Jiren Sun (Eli Lilly and Company)
Co-authors: Tuo Wang (Eli Lilly and Company), Yu Du (Eli Lilly and Company)
Area under the curveChronic kidney diseaseComposite endpointsCumulative disease burdenRestricted mean time in favor of treatmentClinical trial methodology
Competing Risk Analysis in Cardiovascular Outcome Trials
2:20 PM - 2:35 PM
Tuo Wang (Eli Lilly and Company)
Co-authors: Yu Du (Eli Lilly and Company)
competing riskscardiovascular trialsCox modelFine-Gray model
Estimating Treatment Effects in Survival Data with Rare Events
2:35 PM - 2:50 PM
Runjia Li (Eli Lilly and Company)
Co-authors: Mingyang Shan (Eli Lilly and Company), Wenyu Ye (Eli Lilly and Company), Hong Liu-Seifert (Lilly)
Rare eventsTime-to-event outcomesSurvival analysisCausal inferenceDrug development
FLEX-CP-DT: A Flexible Conditional Power Framework for Interim Futility Analysis of Recurrent Event Endpoints with Time-Dependent Treatment Effects
2:50 PM - 3:05 PM
Yanzhao Wang (Regeneron Pharmaceuticals)
Co-authors: Dateng Li (Regeneron Pharmaceuticals)
Negative Binomial ModelTime-varying Treatment effectInterim Futility AnalysisConditional Power
Parametric inference for the average hazard approach in time-to-event analysis
3:05 PM - 3:20 PM
Zihan Qian (Massachusetts General Hospital)
Co-authors: Hajime Uno (Dana-Farber Cancer Institute)
Average intensityHazard ratioIncidence rateMixture populationStratified analysisRobustness
The Negative Binomial Process Model in Respiratory Therapy Trials
3:20 PM - 3:35 PM
Grant Izmirlian (Astrazeneca)
Co-authors: Darren Scott (Astrazeneca)
Negative Binomial ProcessRespiratory Therapy TrialsGamma FrailtyExacerbation counttime to first event
Treatment effect estimation for time-to-event data with intercurrent events under ICH E9 (R1)
3:35 PM - 3:50 PM
Yuhao Deng (Fred Hutchinson Cancer Center)
Co-authors: Shasha Han, Xiao-Hua Zhou (Peking University)
Treatment effectEstimandIntercurrent eventRandomized controlled trialObservational studySurvival analysis
↑